Moderna Inc (WBO:MRNA)
€ 40.79 -0.515 (-1.25%) Market Cap: 16.15 Bil Enterprise Value: 10.93 Bil PE Ratio: 0 PB Ratio: 1.37 GF Score: 61/100

Moderna Inc at Goldman Sachs Healthcare CEOs Unscripted Conference (Virtual) Transcript

Jan 05, 2021 / 01:00PM GMT
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Good morning, everyone, and thank you for joining us for our CEO conference. We're really to pleased have the CEO of Moderna, Stéphane Bancel, with us here this morning.

Questions & Answers

Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

And with that, Stéphane, maybe a first question here about the journey that the company and yourself have gone through. But last year, we saw true validation of the mRNA technology platform as the COVID-19 vaccine 1273 was both created and became your first commercial asset. Could you discuss what the journey has been like for you, as CEO, and what the last year has meant for the company?

Stephane Bancel
Moderna, Inc. - CEO & Director

Well, good morning, everybody, and thank you, Salveen, for having me. Happy new year, everybody.

So we started the company almost 10 years ago now with the idea of using messenger RNA to make protein inside the [body]. At the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot